DMAC — DiaMedica Therapeutics Share Price
0.000.00%
Last trade - 00:00- $178.69m
- $124.66m
- 31
- 22
- 83
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.35 | ||
| Price to Tang. Book | 3.35 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.68% | ||
| Return on Equity | -35.18% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.
Directors
- Richard Pilnik NEC (64)
- Rick Pauls PRE (49)
- Scott Kellen CFO (54)
- Sydney Gilman VPR (67)
- Timothy Mccarthy MDR
- Harry Alcorn OTH (57)
- Amy Burroughs IND (51)
- Michael Giuffre IND (65)
- James Parsons IND (55)
- Charles Semba IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- May 31st, 2019
- Public Since
- January 4th, 2008
- No. of Shareholders
- 25
- No. of Employees
- 18
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 42,747,832
- Address
- 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS, 55305
- Web
- https://www.diamedica.com/
- Phone
- +1 7634965454
- Contact
- Scott Kellen
- Auditors
- BAKER TILLY US LLP
Upcoming Events for DMAC
Q4 2024 DiaMedica Therapeutics Inc Earnings Release
Similar to DMAC
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the DiaMedica Therapeutics share price?
As of Today at 20:16 UTC, shares in DiaMedica Therapeutics are trading at $4.18. This share price information is delayed by 15 minutes.
How has the DiaMedica Therapeutics share price performed this year?
Shares in DiaMedica Therapeutics last closed at $4.18 and the price had moved by +62.02% over the past 365 days. In terms of relative price strength the DiaMedica Therapeutics share price has outperformed the S&P500 Index by +21.07% over the past year.
What are the analyst and broker recommendations for DiaMedica Therapeutics?
The overall consensus recommendation for DiaMedica Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the DiaMedica Therapeutics dividend yield?
DiaMedica Therapeutics does not currently pay a dividend.
Does DiaMedica Therapeutics pay a dividend?
DiaMedica Therapeutics does not currently pay a dividend.
When does DiaMedica Therapeutics next pay dividends?
DiaMedica Therapeutics does not currently pay a dividend.
How do I buy DiaMedica Therapeutics shares?
To buy shares in DiaMedica Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of DiaMedica Therapeutics?
As of the previous close price of $4.18, shares in DiaMedica Therapeutics had a market capitalisation of $178.69m.
Where are DiaMedica Therapeutics shares listed?
Here are the trading details for DiaMedica Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: DMAC
What kind of share is DiaMedica Therapeutics?
Based on an overall assessment of its quality, value and momentum DiaMedica Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a DiaMedica Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in DiaMedica Therapeutics is $7.03. That is 68.17% above the last closing price of $4.18.
Analysts covering DiaMedica Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.62 for the next financial year.
Find out moreWhat is the trend in the DiaMedica Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like DiaMedica Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +37.9%.
As of the last closing price of $4.18, shares in DiaMedica Therapeutics were trading +35.2% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the DiaMedica Therapeutics PE Ratio?
The DiaMedica Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of DiaMedica Therapeutics?
DiaMedica Therapeutics' management team is headed by:
- Richard Pilnik - NEC
- Rick Pauls - PRE
- Scott Kellen - CFO
- Sydney Gilman - VPR
- Timothy Mccarthy - MDR
- Harry Alcorn - OTH
- Amy Burroughs - IND
- Michael Giuffre - IND
- James Parsons - IND
- Charles Semba - IND